Daftar Pustaka

Aakeroy, C.B and Salmon, D.J, 2005, *Building Co-crystals with Molecular Sense and Supramolecular Sensibility,* CrystEngComm, 2005,7(72): 439-448.

Amelinchx, S, Van Dyck, D, Van Landuyt, J, Van Tendeloo, G, 1997, *Electron Microscopy: Principles and Fundamentals,* A Wiley Company.

Ansel, H.C, 1985, *Introduction to Pharmaceutical Dosage Form* : Tejemahan oleh Farida Ibrahim, UI-Press, Jakarta.

AHFS, 2008, *Drug Information*, American Hospital Formulary

Ain, Shabnam, Ain, Qurratul and Parveen, Shama, 2009, *An Overview on Various Approaches Used for Solubilization of Poorly Soluble Drugs,* The Pharma Research: 84-104

Alpha Pharmaceutical, 1999, *Alpha-aciclovir,* (online) http:// www. Medsafe.govt.nz/profs/ datasheet/alphacicilovirtab.htm. diakses tanggal 5 April 2010

Anonim, *Ascorbic Acid,* (online) *www. Inchem .org/documents/ pims/pharm/ ascorbic.htm. diakses tanggal 07 April 2011*

----------,*Differential Scanning Calorimetry,* 2005 (online) http://pslc. ws/macrogess/ dsc.html. Department of Polymer Science, University of Southern Missisipi, diakses tanggal 27 Juni 2010

Arnal, J, Gonzales-Alvares, I, Bermejo, M, Amidon, G.L, Junginger, H.E, Kopp, S, Midha, K.K, Shah, V.P, Stavchansky, S, Dressman, J.B, Barends, D.M. 2008, *Biowaiver Monographs for Immediate Release Solid Oral Dosage Form: Aciclovir,* Journal of Pharmaceutical Sciences, Vol.97 : 5061 – 5073

Basavoju, S, Bostrom, D, Velaga, S.P. 2007, *Indomethacin-Saccharin Cocrystal: Design, Synthesis and Preliminary Pharmaceutical Characterization,* Pharmaceutical Research, Vol.25: 537 – 541

Bhatt, P.M, Ravindra, N.V, Banerjee, R and Desiraju, G.R, 2005, *Saccharin as a salt former. Enhanced Solubilities of Saccharinates of Active Pharmaceutical Ingridients,* Chem.Commun: 1073-1075

Blagden, N, Berry, D.J, Parkin, A, Javed, H, Ibrahim, A, Gavan, P.T, De Matosa, L.L, Seatona, C.C, 2008, *Current Direction in Co-crystal Growth*, New Journal of Chemistry, Vol.32 : 1659-1672

Braga, D, Grepioni, F, Maini, L, and Polito, M. 2009, *Crystal Polymorphism and Multiple Crystal Form,* Struct Bond 132: 25 – 30

Bethune, S.J, 2009, *Thermodinamic and Kinetic Parameters that Explain Crystallization and Solubility of Pharmaceutical Cocrystal,* Disertasi: University of Michigan.

Carstensen, J.T, 1998, *Pharmaceutical Preformulation*, Technomic Publishing Company, Lancaster, Pennsyilvania

Cao Wey-Yun, 2007, *Combined Used of Acyclovir Vitamin C with Interferon in Treating Herpes Simple Keratitis,* Journal of Shandong Medical College

Childs, S. 2007, *Cocrystallization Methods*, US Patent Application

Crowley, PJ and Martini L.G., 2004, *Formulation Design: New Drugs from Old,* Drugdiscoverytoday.com. 537 – 542

Drug Bank, 2009, *Drug Card for Aciclovir (DB00787)*, (online) http://www.drugbank.ca/drugs/DB00787. diakses tanggal 5 April 2010

Dressmann and Kramer, 2005, *Pharmaceutical Dissolution Testing*, Taylor and Francis. London, New York, Singapore

Direktorat Jenderal Pengawasan Obat dan Makanan, 1995, *Farmakope Indonesia*, Edisi IV, Departemen Kesehatan RI, Jakarta

Doherty, M.F, 2008, *From Form to Function: Crystallization of Active Pharmaceutical Ingredients,* AIChE Journal, Vol.54.7 : 1682-1688

Ganiswarna, S.G.,2002, *Farmakologi dan Terapi*: Edisi 4, Bagian Farmakologi Fakultas Kedokteran Universitas Indonesia, Jakarta

Hammod, C, 2009, *The Basic of Crystallography and Diffraction*, Oxford University Press. New York

Hetal, T. Bindesh, P. and Sneha, T.,2010, *A Review on Technique for Oral Bioavailability Enhancement of Drugs,* International Journal of Pharmaceutical Sciences Review and Research, Vol.4: 203-223.

Hilfiker, R, 2006, *Polimorphism: in Pharmaceutical Industry*, WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

Jayasankar, A, Somwangthanaroj, A, Shao, Z.J, and Hornedo, N.R, 2006, *Cocrystal Formation During Cogrinding and Storage is Mediated by Amorphous Phase,* Pharmaceutical Research, Vol.23: 2381-2392

Jones, W, Motherwell,W.D.S, and Trask, A.V. 2006, *Pharmaceutical Cocrystal: An Emerging Approach to Physical Property Enhancement,* MRS Bulletin, 31: 875-879

Karki, S, Friscic, T, Jones, W, and Motherwell, S.W.D. 2007, *Screening for Pharmaceutical Cocrystal Hydrates via Neat and Liquid-Assisted Grinding,* Molecular Pharmaceutics, Vol.4: 347 – 354.

Kumar, S, Parkash, C, Kumar, P, and Singh, S.K, 2009, *Applicatin of Some Novel Technique for Solubility Enhancement of Mefenamic Acid, A Poorly Water Soluble Drug.* International Journal of Pharmaceutical Science and Drug Research, Vol.1 : 164-171

McMahon, J, Peterson, M, Zaworotko, M.J., Shattock, T, Hickey, M.B., 2010. *Pharmaceutical Co-crystal, Composition and Related Methods of Use,* United States Patent: US 7,803,786,B2.

Morisette, S.L, Almarsoon, O, Peterson, M.L, Remenar, J.F, Read, M.J, Lemmo, A.V, Ellis, S, Cima, M.J, and Gardner, C.R, 2003, *High-troughput Crystallization: Polimorphs, Salt, Co-crystals and Solvate of Pharmaceutical Solids,* Advanced Drug Delivery Reviews 56: 275-300

McNamara, D.P, 2006, *Use of Glutaric Acid Cocrystal to Improve Oral Bioavailability of a Low Solubility API,* Pharmaceutical Research, Vol. 23: 1888-1897.

Mirza, S, Miroshnyk, I, Heinamaki,J, Yliruusi, J. 2008, *Co-Crystals: An Emerging Approach or Enhancing Properties of Pharmaceutical Solids,* Dosis, Vol.24 : 90-96.

Nai-Ning, Shao-Yu, and Chang-Xiao, 2004, *Overview of Factors Affecting Oral Drug Absorption*, Asian Journal of Drugs Metabolism and Pharmacokinetics, Vol. 4(3). 167-176

Peterson, M.L, Hickey, M.B, Zaworotko, M.J, and Almarsson,O. 2006, *Expanding the Scope of Crystal Form Evaluation in Pharmaceutical Science,* J Pharm Pharmaceut Sci, Vol 9 (3): 317-326

Rodriguez.N, Nehm, S.J, and Jayasankar, A. 2007, *Cocrystal: Design, Properties and Formation Mechanisms,* Encyclopedia of Pharmaceutical Technology, Informa Healthcare: 615 – 633

Rowe, Raymond C, Sheskey, Paul J, and Owen, Sian C, 2006, *Handbook of Pharmaceutical Excipient,* 5th edition, Pharmaceutical Press, London.

Seefeldt, K, Miller, J, Alvarez, F, and Rodriguesz,N . 2006, *Crystallization Pathway and Kinetics of Carbamazepine-Nicotinamide Cocrystal From the Amorphous State by In Situ Thermomicroscopy, Spectroscopy, and Calorimetry Studies,* Journal of Pharmaceutical Science, Vol.96, 2007: 1147-1158

Settle, F, 1997, *Handbook of Instrumental Techniques for Analytical Chemstry,* Prentice Hall PTR, Upper Saddle River

Schultheiss, N and Newman, A, 2009, *Pharmaceutical Cocrystal and Their Physicochemical Properties*, Crystal Growth and Design, Vol.9 : 2950 – 2967

Shan, N and Zaworotko, M.J.,2008, *The Role of Cocrystal in Pharmaceutical Science,* Drug Discovery Today, Vol.13: 440 – 446

Sekhon, BS., 2009, *Pharmaceutical Co-crystal- a Review*, Ars Pharm, Vol.50 : 99 – 117

Shiraki, K, Takata, N, Takano, R, Hayashi, Y, and Terada, K. 2008, *Dissolution Improvement and The Mechanism of The Improvement from Cocrystallization of Poorly Water Soluble Compounds,* Pharmaceutical Research, Vol.25: 2581-2592.

Shinde, A.J, 2007, *Solubilization of Poorly Soluble Drugs: A Review. (*Online*)* http://www.pharmainfo.net/review/solubilization-poorly-soluble-drugs-review, diakses 15 Januari 2010.

Swarbrick, J, 2007, *Encyclopedia of Pharmaceutical Technology,* Third Ed. Informa Healtcare, New York, London.

Trask, A.V, Motherwell, W.D.S, and Jones, W. 2004, *Solvent-drop Grinding: Green Polymorph Control of Cocrystallisation,* Chem.Commun., 2004: 890-891

Trask, A.V, Shan, N, Motherwell, W.D.S, Jones, W, Feng, S, Tan, R.B.H, Carpenter, K.J. 2005, *Selective Polymorph Transformation via Solvent-drop Grinding,* Chem.Commun., 2005: 880 – 882

Trask, A.V, Motherwell, W.D.S, and Jones, W. 2006, *Physical Stability Enhancement of Theophyllline via Cocrystallization,* International Journal of Pharmaceutics, 320: 114 – 123

Trask, A.V, Streek, J.V, Motherwell, W.D.S, and Jones, W 2005, *Achieving Polymorphic and Stoichiometric Diversity in Crystal Formation: Importance of Solid-State Grinding, Powder X-Ray Structure Determination and Seeding,* Crystal Growth and Design, Vol. 5(6): 2233 – 2241.

Trask, A.V and Jones, W, 2005, *Crystal Engineering of Organic Cocrystal by the Solid-State Grinding Approach,* Tur Curr Chem, 251: 41-70.

Trask, A.V, Motherwell, W.D, and Jones, W. 2004, *Pharmaceutical Cocrystallization: Engineering a Remedy for Caffeine Hydration,* Crystal Growth & Design, 5: 1013 – 1021

Thomson Healthcare. Online *Micromedex Healthcare Series*, http://www.micromedex.com/products/hcs/. Diakses tanggal 5 Maret 2010

USP 29 – NF 24, *Acyclovir*, (online) http ://www.pharmacopeia.cn/ v29240/ usp29nf24s0_m890.html. diakses. diakses 5 April 2010

Vishweshar, P, McMahon, J.A, Peterson, M.L, Hickey, M.B, Shattock, T.R, and Zaworotko, M.J. 2005, *Crystal Engineering of Pharmaceutical Co-crystal From Polymorphic Active Pharmaceutical Ingredients,* Chem.Comm, 4601 – 4603

Yadav, A.V, 2009, *Co-crystal: A Novel Approach to Modify Physicochemical Properties of Actice Pharmaceutical ingridients,* Review Article. Vol.71: 359 – 370.

Lampiran 1 : Skema Kerja

SKEMA KERJA



Gambar 18 : Skema kerja karakterisasi struktur dan uji disolusi kokristal Asiklovir-Asam Askorbat.

Lampiran 4 : Hasil analisis puncak difraksi sinar X

a. Hasil analisis puncak sampel Asiklovir

No	2-THETA	INT.	WIDTH	d	I/Io
1	43,640	98	0,450	2,027	86
2	44,600	113	0,360	2,030	100
3	50,700	40	0,300	1,799	35
4	64,620	11		1,441	9
5	74,720	46	0,480	1,269	40

b. Hasil analisis puncak sampel asam askorbat

No	2-THETA	INT.	WIDTH	d	I/Io
1	43,600	110	0,510	2,074	74
2	44,520	149	0,330	2,033	100
3	50,820	36	0,300	1,795	24
4	64,620	13		1,441	9
5	74,780	35	0,540	1,269	23

Lampiran 8 : Tabel Data Disolusi Asiklovir

Waktu (menit)	Per-Lakuan	Serapan	Kadar (mg/1000 ml)	Kadar (mg/900 ml)	Faktor koreksi	Setelah koreksi	% disolusi
5	1 2	0,849 0,971	51,6250 59,2500	46,4625 53,3250			
Rata-rata		**0,91**	**55,4375**	**49,8937**	**0**	**49,8937**	**49,89**
10	1 2	1,031 1,130	63,0000 69,1875	56,7000 62,2687			
Rata-rata		**1,080**	**66,0937**	**59,4843**	**0,3304**	**59,8147**	**59,81**
15	1 2	1,092 1,148	66,8125 70,3125	60,1312 63,2812			
Rata-rata		**1,12**	**68,5625**	**61,7062**	**0,6732**	**62,3784**	**62,38**
20	1 2	1,117 1,155	68,3750 70,7500	61,5375 63,6750			
Rata-rata		**1,136**	**69,5625**	**62,6062**	**1,021**	**63,6272**	**63,63**
25	1 2	1,135 1,166	69,500 71,4375	62,5500 64,2937			
Rata-rata		**1,150**	**70,4687**	**63,4218**	**1,3733**	**64,7951**	**64,80**
30	1 2	1,171 1,164	72,0000 71,3125	64,8000 64,1812			
Rata-rata		**1,167**	**71,6562**	**64,4906**	**1,7316**	**66,2222**	**66,22**
45	1 2	1,174 1,169	71,9375 71,6250	64,7437 64,4625			
Rata-rata		**1,171**	**71,7812**	**64,6031**	**2,0905**	**66,6936**	**66,69**
60	1 2	1,174 1,169	71,9375 71,6250	64,7437 64,4625			
Rata-rata		**1,172**	**71,7812**	**64,6031**	**2,4494**	**67,0525**	**67,05**

Lampiran 9 : Tabel Data Disolusi Kokristal Asiklovir-Asam Askorbat (1:1)

Waktu (menit)	Per-lakuan	Serapan	Kadar (mg/1000 ml)	Kadar (mg/900 ml)	Faktor koreksi	Setelah koreksi	% disolusi
5	1	1,141	69,8750	62,8875			
	2	1,100	67,3125	60,5812			
Rata-rata		**1,120**	**68,5937**	**61,7343**	**0**	**61,7343**	**61,73**
10	1	1,172	71,8125	64,6312			
	2	1,141	69,8750	62,8875			
Rata-rata		**1,156**	**70,8437**	**63,7593**	**0,3542**	**64,1135**	**64,11**
15	1	1,181	72,3750	65,1375			
	2	1,146	70,1875	63,1688			
Rata-rata		**1,164**	**71,2812**	**64,1531**	**0,7106**	**64,8637**	**64,86**
20	1	1,184	72,5625	65,3062			
	2	1,158	70,9375	63,8437			
Rata-rata		**1,171**	**71,7500**	**64,5749**	**1,0693**	**65,6442**	**65,64**
25	1	1,185	72,6250	65,3625			
	2	1,169	71,6250	64,4625			
Rata-rata		**1,177**	**72,1250**	**64,9125**	**1,4299**	**66,3424**	**66,34**
30	1	1,187	72,7500	65,4750			
	2	1,174	71,9375	64,7437			
Rata-rata		**1,180**	**72,3437**	**65,1093**	**1,7916**	**66,9009**	**66,90**
45	1	1,189	72,8750	65,5875			
	2	1,180	72,3125	65,0812			
Rata-rata		**1,185**	**72,5937**	**65,3343**	**2,1546**	**67,4889**	**67,49**
60	1	1,189	72,8750	65,5875			
	2	1,187	72,7500	65,4750			
Rata-rata		**1,188**	**72,8125**	**65,5312**	**2,5186**	**68,0498**	**68,49**

Lampiran 10: Contoh Perhitungan Uji Disolusi

a. Perhitungan konsentrasi dalam 1000 ml

   Contoh untuk asiklovir pada 5 menit.

   Persamaan garis kurva baku : y = 0,016 x + 0,023

$$X = \frac{y - a}{b}$$

$$X = \frac{0,849 - 0,023}{0,016}$$

$$= 51,6250 \text{ mg} / 1000 \text{ ml}$$

b. Konsentrasi dalam 900 ml

   51,6250/1000 ml x 900 ml

   = 46,4625 mg

c. Perhitungan faktor koreksi

   Faktor koreksi = 5 ml / 900 ml x konsentrasi per 900 ml + faktor koreksi sebelumnya

   Contoh untuk 10 menit,

   5/900 x 59,4843 + 0 = 0,3304

d. Perhitungan konsentrasi setelah koreksi;

   Kadar sebelum koreksi + faktor koreksi

   Contoh: untuk 10 menit

   59,4843 + 0,3304 = 59,8147

3. Persen terdisolusi ;

Kadar setelah koreksi / bobot sampel x 100 %

Contoh: 59,8147 / 100 mg x 100 %

= 59,81 %